GPN Vaccines to Highlight Serotype Independent Bacterial Vaccine Platform at Leading International Vaccines Congresses

Presentations will feature Gamma-PN clinical progress and early Gamma-SU findings supporting a broader approach to human and animal health

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- GPN Vaccines, Inc., a clinical-stage biotechnology company developing a new generation of broadly protective bacterial vaccines designed to overcome the limitations of serotype-specific vaccination, today announced that it will present progress across its vaccine portfolio at the International Society for Vaccines (ISV) Annual Congress, October 12-14 in Antwerp, Belgium, and the World Vaccine Congress Europe, October 19-21 in Amsterdam, Netherlands. The presentations will highlight the Company's approach to developing vaccines designed to protect against bacterial disease regardless of serotype, with evidence from its pneumococcal program, Gamma-PN™, and its veterinary program, Gamma-SU.

GPN's lead vaccine candidate, Gamma-PN, is a serotype-independent pneumococcal vaccine designed to target protein antigens shared across pneumococcal strains, with the goal of providing broad protection against current and emerging serotypes. Unlike existing vaccines that only provide serotype-specific protection, Gamma-PN offers a potentially disruptive approach to pneumococcal vaccination that could eliminate the need to continually reformulate vaccines as new serotypes emerge.

At the World Vaccine Congress Europe, GPN will discuss four completed Gamma-PN clinical studies, which provide evidence of safety, tolerability and immunogenicity, including antibody responses in older adults and responses persisting for at least 12 months in a follow-up study. The presentation will also include preliminary human findings showing that vaccine-induced antibodies can facilitate the killing of multiple pneumococcal serotypes in laboratory assays. GPN is preparing to advance Gamma-PN into a multinational Phase 2 trial.

At ISV, GPN will present Gamma-SU, an investigational vaccine being developed to prevent disease caused by Streptococcus suis in pigs, including post-weaning meningitis. Studies in pigs have shown that Gamma-SU elicits functional antibodies capable of killing multiple S. suis serotypes in laboratory assays. These findings provide early support for applying GPN's whole-cell vaccine approach beyond pneumococcal disease.

"Presenting at two leading, global vaccine conferences gives us an opportunity to showcase the disruptive potential of GPN's bacterial vaccine platform," said Tim Hirst, Chairman and CEO of GPN Vaccines. "Our goal is a future-proof approach that provides broad protection against current and emerging serotypes without continually reformulating vaccines. The progress of Gamma-PN and encouraging early findings with Gamma-SU support our belief that this platform has the potential to change the paradigm of bacterial vaccination."

Details of the presentations are as follows: 

About GPN Vaccines 
GPN Vaccines, Inc. is a clinical-stage biotechnology company developing broadly protective vaccines against bacterial pathogens. The Company's lead candidate, Gamma-PN™, is a whole-cell pneumococcal vaccine designed to provide serotype-independent protection against Streptococcus pneumoniae by generating immune responses to protein antigens common across pneumococcal strains. Gamma-PN has completed four Phase 1 clinical studies demonstrating safety, tolerability, and immunogenicity. GPN is preparing to advance Gamma-PN into Phase 2 clinical development and is applying its vaccine approach to additional emerging bacterial pathogens, such as Streptococcus suis through its Gamma-SU program. For more information, visit www.gpnvaccines.com.

GPN Vaccines:
Tim Hirst
Chairman & CEO
[email protected] 

Media Contact:
Tiberend Strategic Advisors, Inc.
Casey McDonald
+1-646-577-8520
[email protected]

SOURCE GPN Vaccines, Inc.